Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Follow-Up Questions
What is Incyte Corp (INCY)'s P/E Ratio?
The P/E ratio of Incyte Corp is 508.682
Who is the CEO of Incyte Corp?
Mr. Bill Meury is the President of Incyte Corp, joining the firm since 2025.
What is the price performance of INCY stock?
The current price of INCY is $105.77, it has increased 4.13% in the last trading day.
What are the primary business themes or industries for Incyte Corp?
Incyte Corp belongs to Biotechnology industry and the sector is Health Care
What is Incyte Corp market cap?
Incyte Corp's current market cap is $20.6B
Is Incyte Corp a buy, sell, or hold?
According to wall street analysts, 24 analysts have made analyst ratings for Incyte Corp, including 10 strong buy, 8 buy, 15 hold, 1 sell, and 10 strong sell
